{"ticker": {"uuid": "84e01b67-8c74-45f3-addd-e5eaa6419abd", "symbol": "FBIOP", "name": "Fortress Biotech Inc Pref Series A", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Precision Trading with Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (FBIOP) Risk Zones", "summary": "This article analyzes Fortress Biotech Inc.'s (FBIOP) Series A preferred stock, highlighting its neutral near and mid-term readings but a strong long-term positive bias. It identifies an exceptional 48.2:1 risk-reward setup targeting a 12.8% gain versus 0.3% risk. The analysis pr", "url": "https://news.stocktradersdaily.com/news_release/17/Precision_Trading_with_Fortress_Biotech_Inc._9.375_Series_A_Cumulative_Redeemable_Perpetual_Preferred_Stock_FBIOP_Risk_Zones_073026011001_1785388201.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-30T00:50:27", "published_display": "30 Jul 2026 00:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FBIO|Fortress Biotech Inc|Price:3.301|Chg%:-0.049", "summary": "This article provides a comprehensive stock analysis of Fortress Biotech Inc (FBIO), highlighting its strong fundamentals, high growth potential, and \"fairly valued\" status within the Pharmaceuticals industry. It notes high institutional ownership and a \"Buy\" rating from multiple", "url": "https://www.tradingkey.com/markets/stocks/fbio/stock-analysis", "source_name": "TradingKey", "published_at": "2026-07-29T21:40:53", "published_display": "29 Jul 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' $130 Million Series B Financing", "summary": "Fortress Biotech and its subsidiary Urica Therapeutics announced that Crystalys Therapeutics, a clinical-stage biotechnology company, has successfully completed a $130 million Series B financing round. Urica Therapeutics has an equity ownership stake in Crystalys Therapeutics, be", "url": "https://www.moomoo.com/news/post/73577777/press-release-fortress-biotech-and-subsidiary-urica-therapeutics-announce-crystalys", "source_name": "Moomoo", "published_at": "2026-07-28T11:40:53", "published_display": "28 Jul 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics $130 Million Series B Financing", "summary": "Fortress Biotech and its subsidiary Urica Therapeutics announced that Crystalys Therapeutics, in which Urica holds an equity position, closed an oversubscribed $130 million Series B financing. This funding will support the late-stage global clinical development and commercializat", "url": "https://www.marketscreener.com/news/fortress-biotech-and-subsidiary-urica-therapeutics-announce-crystalys-therapeutics-130-million-seri-ce7f51ddd188f726", "source_name": "marketscreener.com", "published_at": "2026-07-28T11:00:00", "published_display": "28 Jul 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Inc (FBIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for Fortress Biotech Inc (FBIO) by business segment. As of April 2, 2025, the company's products Targadox\u00ae, Exelderm\u00ae, and Ximino\u00ae generated revenues of $3.20M, $2.40M, and $287.00K respectively, comprising 3.79%, 2.83%, and 0.34% of the ", "url": "https://www.tradingkey.com/markets/stocks/fbio/revenue", "source_name": "TradingKey", "published_at": "2026-07-27T14:11:07", "published_display": "27 Jul 2026 14:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Inc (FBIO) Institutional Confidence", "summary": "Fortress Biotech Inc (FBIO) has an institutional shareholding score of 3.00, ranking 92nd out of 155 in the Pharmaceuticals industry. The current institutional shareholding proportion is 18.14%, reflecting a 31.58% decrease quarter-over-quarter. James Simons is the largest instit", "url": "https://www.tradingkey.com/markets/stocks/fbio/sentiment", "source_name": "TradingKey", "published_at": "2026-07-27T12:12:07", "published_display": "27 Jul 2026 12:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics\u2019 $130 Million Series B Financing", "summary": "Fortress Biotech and its subsidiary Urica Therapeutics announced that Crystalys Therapeutics, in which Urica holds an equity position, closed a $130 million Series B financing. These proceeds will fund the late-stage global clinical development and commercialization of dotinurad,", "url": "https://www.manilatimes.net/2026/07/27/tmt-newswire/globenewswire/fortress-biotech-and-subsidiary-urica-therapeutics-announce-crystalys-therapeutics-130-million-series-b-financing/2392091", "source_name": "The Manila Times", "published_at": "2026-07-27T12:11:07", "published_display": "27 Jul 2026 12:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Inc (FBIO) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Fortress Biotech Inc (FBIO), listing major individual and institutional holders. It provides a breakdown of shareholder types, institutional shareholding over several quarters, and recent shareholder activity with changes in holdi", "url": "https://www.tradingkey.com/markets/stocks/fbio/ownership", "source_name": "TradingKey", "published_at": "2026-07-27T07:11:23", "published_display": "27 Jul 2026 07:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech, Inc. Revenue Breakdown \u2013 NASDAQ:FBIO", "summary": "Fortress Biotech, Inc. (NASDAQ: FBIO) generated $63.26 million in revenue last year, with its Journey segment contributing the most at $61.86 million. The United States was the primary source of revenue, accounting for the entire $63.26 million. This shows a slight increase in ov", "url": "https://www.tradingview.com/symbols/NASDAQ-FBIO/financials-segments/", "source_name": "TradingView", "published_at": "2026-07-26T22:40:20", "published_display": "26 Jul 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Inc (FBIO) Income Statement", "summary": "This article provides an income statement for Fortress Biotech Inc (FBIO), detailing its quarterly and annual financial performance. It includes metrics such as total revenue, cost of revenue, operating expenses, and net income, alongside year-over-year comparisons. The page also", "url": "https://www.tradingkey.com/markets/stocks/fbio/income-statement", "source_name": "TradingKey", "published_at": "2026-07-26T21:39:43", "published_display": "26 Jul 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech, Inc. - 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock", "summary": "This article provides details on the revenue breakdown for Fortress Biotech, Inc.'s 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (FBIOP). Last year, the company generated $63.26 million USD in total revenue, with its Journey segment contributing $61.86 million ", "url": "https://www.tradingview.com/symbols/BOATS-FBIOP/financials-segments/", "source_name": "TradingView", "published_at": "2026-07-26T02:41:32", "published_display": "26 Jul 2026 02:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FBIO|Fortress Biotech Inc|Price:3.340|Chg%:-0.090", "summary": "Fortress Biotech Inc (FBIO) is trading at $3.34, down 2.62%. The company's fundamentals are considered healthy with high growth potential, and its valuation is seen as fairly valued within the Pharmaceuticals industry. Analysts have rated it a \"Buy\" with a target price of $11.00,", "url": "https://www.tradingkey.com/markets/stocks/fbio", "source_name": "TradingKey", "published_at": "2026-07-24T20:39:49", "published_display": "24 Jul 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Inc (FBIO) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Fortress Biotech Inc (FBIO) has a robust financial score of 8.91, ranking 26 out of 155 in the Pharmaceuticals industry, indicating strong financial health and high operating efficiency. The company reported a significant year-over-year revenue increase of 22.06% and a net profit", "url": "https://www.tradingkey.com/markets/stocks/fbio/financial-health", "source_name": "TradingKey", "published_at": "2026-07-24T20:39:49", "published_display": "24 Jul 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech stocks lead healthcare's overbought list as earnings picks up (XLV:NYSEARCA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOWXk4aklwck0tTWtFYkluLThYNGtxX3RHTHE0YlM2WnFRZG1YTk5mSW5oLVgzVGI3VW4zcTJVeWRDX2JyYWxLaVZ3cEVZS1k3OW56dkZqTnAtS2d4bzY1c2hOdTQ4c0FmeDF5Njdlam1KZURTSGNJMzZPQU9FY18tX3QxUzdCbmVfbEpMbWdJamZIVUVTVkVOUWhvTTN2LUs3Zmx0VG41dWo3Zw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-23T07:00:00+00:00", "published_display": "23 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Preferred Stock (FBIOP) Holds Steady Near Support Amid Low Volume Trading - Modified Schiff", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxNSW9NQzdYblppeERqanVEa1BIdDQzWE1OanJvRTRWQ3V6VUhwQ2dnRXdpWDY2aW50YmZZLW9zdGplXzJDVHBxTU9URlJaRHdscUdZQldLLUtlcWE1WGxtNEg0TkZ5X3dZVElVb1E4LWhoemRkZWFrT3htRG1GZ3FpNlhXbFUwUVNoVlp6VFpkVjZaYTloOGdsVDJ5SDgxeTctYUhBVXVSZk13UFdBYnpFQ0YzMEJQTU1zZ19Ccm9ycklnSUFmQjhzX0tFdVQ?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-21T14:42:07+00:00", "published_display": "21 Jul 2026 14:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Preferred Stock (FBIOP) Holds Steady Near Support Amid Low Volume Trading - Synthetic Short", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxNUzNaaW1FdEl2cnlldnpOQjRoSHNOTnNFU3VPODR5NVRBOG05UDhHNFFGZmhGaFJoUlE2RVpRSDBRQ2xrX1dhRXJpR3ptdjVWWTZuNXJjMXVSX1h5SzAyQWp3T21tZnJhbkhPcWRldFZ5SGthQnZFREtiWGk1LWZId3VfTTM2cjUtUjNWUlAyODYtOGpLRWJOVjdBMW0ydXFjUEE2V3YtVHR6UG1wWTBVeDNHOUFfWEZ3MU1SYjBwWnVBMWFaS2JVekN3?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-21T07:00:00+00:00", "published_display": "21 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Technical Reactions to FBIOP Trends in Macro Strategies", "summary": "This article analyzes Fortress Biotech Inc. (NASDAQ: FBIOP) using AI models to provide technical reactions and trading strategies. It highlights divergent sentiment, a mid-channel oscillation pattern, and an exceptional risk-reward setup. Three distinct trading strategies\u2014Positio", "url": "https://news.stocktradersdaily.com/news_release/139/Technical_Reactions_to_FBIOP_Trends_in_Macro_Strategies_071826022402_1784399042.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-18T14:41:32", "published_display": "18 Jul 2026 14:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T07:00:00+00:00", "published_display": "16 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "CNB0 Bond Coupon Profile \u2014 Rate & Payments", "summary": "This article provides a brief overview of the CNB0 bond coupon profile, detailing its interest rate and payment structure. It highlights the importance of the coupon as the interest rate paid on a bond by Fortress Biotech, Inc. for its 9.375% Series A Cumulative Redeemable Perpet", "url": "https://www.tradingview.com/symbols/FWB-CNB0/profile-coupon/", "source_name": "TradingView", "published_at": "2026-07-15T03:13:28", "published_display": "15 Jul 2026 03:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_gFBVV95cUxPTFlzc3AzYmlzdG0zQXQ4eEd2TDJlT0h5bGlMVUdRd0JjLWd2Qm5kVU5oR3VWX19BVENjbXlqcVM3NFMwT0FDTHQwY05WNk96aGhpM3pQMWZWcExyeGVZaXFkeDVtMTlwVnM5RlNaTTNHYVhVYkFDQ3kwczlFeTlUN1huR1FJbHdBT2ZTajJ6VEFPVFI0MkZoMzRIMjc2Y182WEJpREFjZno4VzRDZF85R1lrdjNhVi1pYm01RHJDRTJmWHF0OHpMOXFyLTJuLWgydEFBX3JGTGtBSzlVSmdER2NnVUdJbERJVkRxOGo1MFlHMHZXMUxZU0hFOWxIdw?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-12T07:00:00+00:00", "published_display": "12 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Fortress Biotech Preferred Stock (FBIOP) Edges Lower as Support Levels Are Tested - Chaikin Flow", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNcE9ScFlFNWQ2VEpoQjNCS3doY29VWEFmREE5cHdnOUxLdkdXSXE0MVFad1lHYll6emVFV2FTakRxcmhaRVVzaEcya0x1Yk00WU9aRUZUSWIyXzBkdHd0SnNXcDM5Um1sTGtpM0dzQTRpYkhpcnNMem5EbjQ4M1U5cXlINEZvTXJpeEsxdFFWcHBQelZPTmRZR1dqOW01WjhIWnpHRkFQN1llOEJtME5CVERpaEM3ZnZiZGd5SzZmVQ?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-11T07:00:00+00:00", "published_display": "11 Jul 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Preferred Stock (FBIOP) Edges Lower as Support Levels Are Tested - NAAIM Leverage", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxNSXprejRVR1NzYnF2SmQ2OGp1SFloUG80OGIyYUpNalpOdVB4ZE5lTGNaSFRwWnMwVGxvRTgxV3FWQ1VfM2ZyVmpJNjhUcXpVMTRjdnJBVTlPZ21EakVTVHNwekVTQlpfclVKRTdVRlNXdzRzMHo2S1FpbmtORXNEY1hoQkFtYkV5cHlZdFFCSmJsQlppZmQxUjRlclZ6OENVT2pZN05adVdVaklsSHJiMGNlSFRBaUt0dVIxVkdHQzdDUQ?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-11T07:00:00+00:00", "published_display": "11 Jul 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Preferred (FBIOP) Q1 2026 Earnings: EPS Misses Estimates by over 400%, Stock Declines - Interim Report", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxOVFFBQjhfeDVqSHI2Y1gySWdMYkE5OTdGMU5Gajk1R0RYNzdaeks5dXFyUXA5dnRGU1NCQVlHSG52SHdmdTk5WlJuQ2JoVnJvdTdPMWtnTDVoNjV2ZXdYR3ZKM2czRVBlb3FhekxEemQwSEpMSndoMkFrcW9MMTJzTGdxUlVNeUpNV0JZbDRQanpqSDkwZ2g3SFoxalkzR2tiU2t6c3pubWpYZGx1Z1lfMlY5bUFjQzZobkdPQ29LVEh2QmhGUlp4RHpzLTAxdm5KSEJpYlBPQmw5dw?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-11T07:00:00+00:00", "published_display": "11 Jul 2026 07:00", "sentiment": "negative", "sentiment_pct": 5, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (FBIOP) Q1 2026 Earnings: EPS Misses Estimates Significantly, Stock Declines - Earnings Weakness Phase", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwJBVV95cUxQRW1XbUd2SzlvVVluOGJldW9ZazNXRUZQWVZRc3Q3cmgxYnZJOURCOHdjYWR2b2JkMENJUDVKZk1vU1UyS0hOd3E5cGpmNU4wM3lRdlYtRmt1VjhhOFpKQk93VTJQX0drYUlSc3g3RTJGb1hXakRsbFpqSFRvYm9TdmxEelJ6UElEN3hsTllsUHlUY2JyckY0X19WTWxaUzNibmZtalM1QkxoNUQ5WHVHZUx6RXRnTXVUTVU3QkQ4NDZtYkZZR3BnZDkxeXRzNjVNREJhNjhRLWZLUDJMQ0hXeTdEUU9RQkxKOTJZd25uRXIxYm9jcWp1bzYzU1pnaFdhT2Z5RXJ4UzJNSGJsU3dkdzRUUlk4NWxVUEZ5NVdhelhnYXlWNE9J?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-10T17:36:44+00:00", "published_display": "10 Jul 2026 17:36", "sentiment": "negative", "sentiment_pct": 5, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech highlights its biotech portfolio strategy as a Nasdaq-listed micro-cap", "summary": "Fortress Biotech, a Nasdaq-listed biopharmaceutical company, emphasizes its strategy of a diversified portfolio managed through subsidiary companies and partnerships. This approach focuses on licensing, clinical development, and eventual commercialization of novel therapeutics, p", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/fortress-biotech-highlights-its-biotech-portfolio-strategy-as-a/69725670", "source_name": "AD HOC NEWS", "published_at": "2026-07-08T19:27:00", "published_display": "08 Jul 2026 19:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mustang Bio (MBIO) Registration Filing Summary", "summary": "Mustang Bio (MBIO) is a clinical-stage biopharmaceutical company focused on CAR T therapies, operating as a majority-controlled subsidiary of Fortress Biotech. The company has an accumulated deficit of $395.8 million, no product sales to date, and faces significant doubt about it", "url": "https://quartr.com/events/mustang-bio-inc-mbio-registration-filing_FP0KdRuG", "source_name": "Quartr", "published_at": "2026-07-07T19:11:20", "published_display": "07 Jul 2026 19:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech focuses on specialty pharma growth and licensing model", "summary": "Fortress Biotech pursues a portfolio strategy in specialty pharmaceuticals, building and licensing therapies through its partner companies, and diversifying its pipeline to mitigate risk. The company focuses on specialty and rare disease markets, aiming for premium pricing and st", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/fortress-biotech-focuses-on-specialty-pharma-growth-and-licensing-model/69715488", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T15:30:00", "published_display": "07 Jul 2026 15:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Inc highlights its specialty pharma model as investors assess long-term prospects", "summary": "Fortress Biotech Inc operates a specialty pharmaceutical and biotech portfolio strategy, utilizing a holding-style structure with multiple subsidiaries to develop product candidates across various disease areas like oncology and rare diseases. This approach aims to diversify risk", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/fortress-biotech-inc-highlights-its-specialty-pharma-model-as-investors/69680167", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-03T15:41:31", "published_display": "03 Jul 2026 15:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trading the Move, Not the Narrative: (FBIOP) Edition", "summary": "This article provides an AI-driven analysis for Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (NASDAQ: FBIOP), highlighting weak near-term sentiment but strong long-term potential. It offers three distinct institutional trading strategies\u2014P", "url": "https://news.stocktradersdaily.com/news_release/98/Trading_the_Move,_Not_the_Narrative:_FBIOP_Edition_062626055202_1782467522.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-26T05:52:00", "published_display": "26 Jun 2026 05:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Fortress Biotech Inc For: 24 June By Investing.com", "summary": "This article announces the filing of Form 4 for Fortress Biotech Inc. on June 24. It is a brief report from Investing.com, providing basic information about the regulatory filing. The content focuses on the public disclosure of insider transactions for the company.", "url": "https://za.investing.com/news/stock-market-news/form-4-fortress-biotech-inc-for-24-june-93CH-4343110", "source_name": "Investing.com South Africa", "published_at": "2026-06-25T22:11:08", "published_display": "25 Jun 2026 22:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Fortress Biotech, Inc. \u2013 NASDAQ:FBIO", "summary": "This article displays the \"Price to sales forward\" financial metric for Fortress Biotech, Inc. (NASDAQ: FBIO). The content is primarily a data presentation, indicating the company's financial overview on the TradingView platform.", "url": "https://www.tradingview.com/symbols/NASDAQ-FBIO/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T12:10:10", "published_display": "25 Jun 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Journey Medical (DERM) Stock Draws Fresh Price Target Split After Fortress Valuation Changes", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/journey-medical-derm-stock-draws-042922197.html", "source_name": "Simply Wall St.", "published_at": "2026-06-25T04:29:22+00:00", "published_display": "25 Jun 2026 04:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech (NASDAQ: FBIO) CFO receives 400,000 RSU award", "summary": "Fortress Biotech's CFO, Jin David, was granted 400,000 restricted stock units (RSUs) as equity compensation, increasing his total holdings to 1,651,571 shares. These RSUs will vest in four equal annual installments, with the first vesting on January 5, 2027, contingent on his con", "url": "https://www.stocktitan.net/sec-filings/FBIO/form-4-fortress-biotech-inc-insider-trading-activity-bf9173876cd9.html", "source_name": "Stock Titan", "published_at": "2026-06-25T02:42:14", "published_display": "25 Jun 2026 02:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Fortress Biotech, Inc. \u2013 NASDAQ:FBIO", "summary": "The article provides a financial snippet for Fortress Biotech, Inc. (NASDAQ: FBIO), focusing on its enterprise value to revenue forward metric. It displays the current value, change, and percentage change for this financial indicator, noting that the market is closed without rece", "url": "https://www.tradingview.com/symbols/NASDAQ-FBIO/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T00:42:14", "published_display": "25 Jun 2026 00:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Preferred Stock (FBIOP) Holds Steady Near Midpoint of Recent Range - PCR Moving Average", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOT2g0Z0JENXVoU1g3VFIxZjFDaDlKVUdHRnMyTEl3RFAzaWNHazIwci1aSzRkUW9RRWlIX1lRV3c0aGgtemY1dWpxMGlIRzlmZGpaZzZObXROeVFRTzRHdVlWdjJmT3J5VS0yRWhEMnNWRmxmZ1J1bXNPVzNKTENsRF84OXIxSDZ2Wldzcl84d1VHR2hTamRkQWpNWmlEZWNDQUV3cUplbjBKLVQ4SFo5SzNEWTFIaFA3TENhNjdSdlBJZU0?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-23T18:44:07+00:00", "published_display": "23 Jun 2026 18:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Preferred Stock (FBIOP) Faces Resistance, Slides 2.3% in Quiet Session - Early Entry Signals", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxPQnJLQ21idVFyVlRTdkpFOXVfT0h1emJVMGFlOVZKZmt3c1ZGY3ZrWTY1RXNDSTFLd0c1VWliMnBsWkJYV1U3VGV5Y1RCQm5KWmtLYVhRVFVWeTlWekhaUGxOdDUtdlhPdFBkVWFIOGUycUUtNjh5bFV2VkNiLWlCY1YxdVY1dFVPWUFScWRHQTgwZlNJR0laQ3dsNFBfMmpCXzh6T0NFVFB2TktRZXB5ZlJ0VVRUU25CRFFsNlA4ZTJWZlE?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Preferred Stock (FBIOP) Faces Resistance, Slides 2.3% in Quiet Session - Quote Data", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxPbThJeVZQNXotS3RiQk1zSkFIc29PUVpmWjJFMWVxWUR6V0IyU3BaYlh2czBaekRnd3UyNlZrd2FpcEZwWVAzd1RlVVhzc25iWFY0UTUtNGRhQkRxdW50Q01oRFVWdjJncnpnLXVrSndCZHFGakdRcHBJTjZfZHAtYkpOZlUwOFlVY05qSUtGampHX0wzNlhDT1JENU5pcVFGdjRYc2d1Sks1elNmYTlUTm11MnVBU2JrWVBsMTdjeDd1MGhxWnc?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech: Is It Time To Pay The Deferred Preferred Stock Dividends? (FBIO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNelREUjIyQ2pLUExaUmZWMVVTNXliRzBxbHpBODdfZWFsbm9USF9FenlxMGpOazhkT094dTRMd1Z5NXZjejlKT0E5bklHQkhsWHNxTzY5bzVZSzN0Mk5uY0Y4emJLajcwY1RyY3phdmhxVFhxVXdOdDFfSFpZWmVTd3lwdnV3c1B3eVlETVNkakJCNEhiVlV5M3c2MGJiOWNzVzdEN1NMcTV0a24wVl80?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Preferred (FBIOP) Gains 1.21% as Income Seekers Eye 9.375% Yield - Cumulative Volume", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPT0Q1UzZDQ1pDVzVVRWx4VWdsc3hwMmpSVWJ0c2JJclB5NTdyLVpVOGYyLTE5b2twZV9scXd4SjVjVkMzdWluVW5NdzNuRlduaHZwWlVwc1liZm9taHAxQklSOWRsa003X1BOMjhIUThKalJfU3RFM2tSbjdCb3JaQjFjV3pJYWVlbnhfekJsanVtekpLa3MyYTEwcndQODBDQ3hjNlB4YlZ6RzdzV196VXlDV0NpY0pq?oc=5", "source_name": "po-news-eg.net", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Preferred (FBIOP) Gains 1.21% as Income Seekers Eye 9.375% Yield - Standard Deviation", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOSTZ5WHVWdVl5Mkd2eFJGWXY0MWlpX0ZjZU9OVXpEVlp1MkJQcmN4MmRRNXBjZkYwcndxbzFXZ2dVWHRRTW9WdGhtbmFMR0FvZHpWb1lMb2RnSUpiS1ZFRUc3Ql9Pbk0zaWZuNmxWaU84ZkZMZnFSTXhLTFVSVU52SnQta0ZxVzRycmZxMGxxVklHZTJocFp5MzhWa042RTZ4RjllclV1Q1FiNzBRZEZocUM0YjNGUHpDMGN3Zw?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech to Participate in A.G.P.\u2019s Annual Virtual Healthcare Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/fortress-biotech-participate-g-p-123000153.html", "source_name": "GlobeNewswire", "published_at": "2026-05-18T12:30:00+00:00", "published_display": "18 May 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Fortress Biotech: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/fortress-biotech-q1-earnings-snapshot-205038341.html", "source_name": "Associated Press", "published_at": "2026-05-14T20:50:38+00:00", "published_display": "14 May 2026 20:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/fortress-biotech-reports-first-quarter-201000966.html", "source_name": "GlobeNewswire", "published_at": "2026-05-14T20:10:00+00:00", "published_display": "14 May 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSG1pQzVIRmhqTkhiWXozT29mTWM0UERfakxmOTZzdm5TZ24wZTVqLUpSWlFyWGVmYnlicGE3ZVYxOVotWU5naGM5aUZVakItUGJLTk1ZVE1mclRHd1N3N0FIWkV2TzFrT2lMNFRjcHhnVVBzTk5vNUFkLTgwNExtRWJYN1hVZzRkVjRlTktkNk1jcnpfQklCamN3NA?oc=5", "source_name": "Barron's", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech: The PRV Catalyst That Could Reprice This Microcap", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPQi14VVlUSUNmM1JubXFxZ19jVkNBOWpkU01zWEt6Mm4zTnZwSXRhZ3pMVFhFSmhCQUp4ZHZxUjNsUnZ0cUR4UEhRZkI3aERudlFhdTZFcUFxOVJGb044bElybWk1a2VPbnpqRFdGSzBRRHphdlVQYjVmZVNKd2tERUxFcENqZ252YWYtSnhHRXFwcGxkYnVGekZJdW91QUMwUDVQcEVqd2JRNm8?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-02-19T08:00:00+00:00", "published_display": "19 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Precision Trading with Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (FBIOP) Risk Zones", "summary": "This article analyzes Fortress Biotech Inc.'s (FBIOP) Series A preferred stock, highlighting its neutral near and mid-term readings but a strong long-term positive bias. It identifies an exceptional 48.2:1 risk-reward setup targeting a 12.8% gain versus 0.3% risk. The analysis pr", "url": "https://news.stocktradersdaily.com/news_release/17/Precision_Trading_with_Fortress_Biotech_Inc._9.375_Series_A_Cumulative_Redeemable_Perpetual_Preferred_Stock_FBIOP_Risk_Zones_073026011001_1785388201.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-30T00:50:27", "published_display": "30 Jul 2026 00:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FBIO|Fortress Biotech Inc|Price:3.301|Chg%:-0.049", "summary": "This article provides a comprehensive stock analysis of Fortress Biotech Inc (FBIO), highlighting its strong fundamentals, high growth potential, and \"fairly valued\" status within the Pharmaceuticals industry. It notes high institutional ownership and a \"Buy\" rating from multiple", "url": "https://www.tradingkey.com/markets/stocks/fbio/stock-analysis", "source_name": "TradingKey", "published_at": "2026-07-29T21:40:53", "published_display": "29 Jul 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' $130 Million Series B Financing", "summary": "Fortress Biotech and its subsidiary Urica Therapeutics announced that Crystalys Therapeutics, a clinical-stage biotechnology company, has successfully completed a $130 million Series B financing round. Urica Therapeutics has an equity ownership stake in Crystalys Therapeutics, be", "url": "https://www.moomoo.com/news/post/73577777/press-release-fortress-biotech-and-subsidiary-urica-therapeutics-announce-crystalys", "source_name": "Moomoo", "published_at": "2026-07-28T11:40:53", "published_display": "28 Jul 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics $130 Million Series B Financing", "summary": "Fortress Biotech and its subsidiary Urica Therapeutics announced that Crystalys Therapeutics, in which Urica holds an equity position, closed an oversubscribed $130 million Series B financing. This funding will support the late-stage global clinical development and commercializat", "url": "https://www.marketscreener.com/news/fortress-biotech-and-subsidiary-urica-therapeutics-announce-crystalys-therapeutics-130-million-seri-ce7f51ddd188f726", "source_name": "marketscreener.com", "published_at": "2026-07-28T11:00:00", "published_display": "28 Jul 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Inc (FBIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for Fortress Biotech Inc (FBIO) by business segment. As of April 2, 2025, the company's products Targadox\u00ae, Exelderm\u00ae, and Ximino\u00ae generated revenues of $3.20M, $2.40M, and $287.00K respectively, comprising 3.79%, 2.83%, and 0.34% of the ", "url": "https://www.tradingkey.com/markets/stocks/fbio/revenue", "source_name": "TradingKey", "published_at": "2026-07-27T14:11:07", "published_display": "27 Jul 2026 14:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Inc (FBIO) Institutional Confidence", "summary": "Fortress Biotech Inc (FBIO) has an institutional shareholding score of 3.00, ranking 92nd out of 155 in the Pharmaceuticals industry. The current institutional shareholding proportion is 18.14%, reflecting a 31.58% decrease quarter-over-quarter. James Simons is the largest instit", "url": "https://www.tradingkey.com/markets/stocks/fbio/sentiment", "source_name": "TradingKey", "published_at": "2026-07-27T12:12:07", "published_display": "27 Jul 2026 12:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics\u2019 $130 Million Series B Financing", "summary": "Fortress Biotech and its subsidiary Urica Therapeutics announced that Crystalys Therapeutics, in which Urica holds an equity position, closed a $130 million Series B financing. These proceeds will fund the late-stage global clinical development and commercialization of dotinurad,", "url": "https://www.manilatimes.net/2026/07/27/tmt-newswire/globenewswire/fortress-biotech-and-subsidiary-urica-therapeutics-announce-crystalys-therapeutics-130-million-series-b-financing/2392091", "source_name": "The Manila Times", "published_at": "2026-07-27T12:11:07", "published_display": "27 Jul 2026 12:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Inc (FBIO) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Fortress Biotech Inc (FBIO), listing major individual and institutional holders. It provides a breakdown of shareholder types, institutional shareholding over several quarters, and recent shareholder activity with changes in holdi", "url": "https://www.tradingkey.com/markets/stocks/fbio/ownership", "source_name": "TradingKey", "published_at": "2026-07-27T07:11:23", "published_display": "27 Jul 2026 07:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech, Inc. Revenue Breakdown \u2013 NASDAQ:FBIO", "summary": "Fortress Biotech, Inc. (NASDAQ: FBIO) generated $63.26 million in revenue last year, with its Journey segment contributing the most at $61.86 million. The United States was the primary source of revenue, accounting for the entire $63.26 million. This shows a slight increase in ov", "url": "https://www.tradingview.com/symbols/NASDAQ-FBIO/financials-segments/", "source_name": "TradingView", "published_at": "2026-07-26T22:40:20", "published_display": "26 Jul 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Inc (FBIO) Income Statement", "summary": "This article provides an income statement for Fortress Biotech Inc (FBIO), detailing its quarterly and annual financial performance. It includes metrics such as total revenue, cost of revenue, operating expenses, and net income, alongside year-over-year comparisons. The page also", "url": "https://www.tradingkey.com/markets/stocks/fbio/income-statement", "source_name": "TradingKey", "published_at": "2026-07-26T21:39:43", "published_display": "26 Jul 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech, Inc. - 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock", "summary": "This article provides details on the revenue breakdown for Fortress Biotech, Inc.'s 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (FBIOP). Last year, the company generated $63.26 million USD in total revenue, with its Journey segment contributing $61.86 million ", "url": "https://www.tradingview.com/symbols/BOATS-FBIOP/financials-segments/", "source_name": "TradingView", "published_at": "2026-07-26T02:41:32", "published_display": "26 Jul 2026 02:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FBIO|Fortress Biotech Inc|Price:3.340|Chg%:-0.090", "summary": "Fortress Biotech Inc (FBIO) is trading at $3.34, down 2.62%. The company's fundamentals are considered healthy with high growth potential, and its valuation is seen as fairly valued within the Pharmaceuticals industry. Analysts have rated it a \"Buy\" with a target price of $11.00,", "url": "https://www.tradingkey.com/markets/stocks/fbio", "source_name": "TradingKey", "published_at": "2026-07-24T20:39:49", "published_display": "24 Jul 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Inc (FBIO) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Fortress Biotech Inc (FBIO) has a robust financial score of 8.91, ranking 26 out of 155 in the Pharmaceuticals industry, indicating strong financial health and high operating efficiency. The company reported a significant year-over-year revenue increase of 22.06% and a net profit", "url": "https://www.tradingkey.com/markets/stocks/fbio/financial-health", "source_name": "TradingKey", "published_at": "2026-07-24T20:39:49", "published_display": "24 Jul 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech stocks lead healthcare's overbought list as earnings picks up (XLV:NYSEARCA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOWXk4aklwck0tTWtFYkluLThYNGtxX3RHTHE0YlM2WnFRZG1YTk5mSW5oLVgzVGI3VW4zcTJVeWRDX2JyYWxLaVZ3cEVZS1k3OW56dkZqTnAtS2d4bzY1c2hOdTQ4c0FmeDF5Njdlam1KZURTSGNJMzZPQU9FY18tX3QxUzdCbmVfbEpMbWdJamZIVUVTVkVOUWhvTTN2LUs3Zmx0VG41dWo3Zw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-23T07:00:00+00:00", "published_display": "23 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Preferred Stock (FBIOP) Holds Steady Near Support Amid Low Volume Trading - Modified Schiff", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxNSW9NQzdYblppeERqanVEa1BIdDQzWE1OanJvRTRWQ3V6VUhwQ2dnRXdpWDY2aW50YmZZLW9zdGplXzJDVHBxTU9URlJaRHdscUdZQldLLUtlcWE1WGxtNEg0TkZ5X3dZVElVb1E4LWhoemRkZWFrT3htRG1GZ3FpNlhXbFUwUVNoVlp6VFpkVjZaYTloOGdsVDJ5SDgxeTctYUhBVXVSZk13UFdBYnpFQ0YzMEJQTU1zZ19Ccm9ycklnSUFmQjhzX0tFdVQ?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-21T14:42:07+00:00", "published_display": "21 Jul 2026 14:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Preferred Stock (FBIOP) Holds Steady Near Support Amid Low Volume Trading - Synthetic Short", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxNUzNaaW1FdEl2cnlldnpOQjRoSHNOTnNFU3VPODR5NVRBOG05UDhHNFFGZmhGaFJoUlE2RVpRSDBRQ2xrX1dhRXJpR3ptdjVWWTZuNXJjMXVSX1h5SzAyQWp3T21tZnJhbkhPcWRldFZ5SGthQnZFREtiWGk1LWZId3VfTTM2cjUtUjNWUlAyODYtOGpLRWJOVjdBMW0ydXFjUEE2V3YtVHR6UG1wWTBVeDNHOUFfWEZ3MU1SYjBwWnVBMWFaS2JVekN3?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-21T07:00:00+00:00", "published_display": "21 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Technical Reactions to FBIOP Trends in Macro Strategies", "summary": "This article analyzes Fortress Biotech Inc. (NASDAQ: FBIOP) using AI models to provide technical reactions and trading strategies. It highlights divergent sentiment, a mid-channel oscillation pattern, and an exceptional risk-reward setup. Three distinct trading strategies\u2014Positio", "url": "https://news.stocktradersdaily.com/news_release/139/Technical_Reactions_to_FBIOP_Trends_in_Macro_Strategies_071826022402_1784399042.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-18T14:41:32", "published_display": "18 Jul 2026 14:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CNB0 Bond Coupon Profile \u2014 Rate & Payments", "summary": "This article provides a brief overview of the CNB0 bond coupon profile, detailing its interest rate and payment structure. It highlights the importance of the coupon as the interest rate paid on a bond by Fortress Biotech, Inc. for its 9.375% Series A Cumulative Redeemable Perpet", "url": "https://www.tradingview.com/symbols/FWB-CNB0/profile-coupon/", "source_name": "TradingView", "published_at": "2026-07-15T03:13:28", "published_display": "15 Jul 2026 03:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Preferred Stock (FBIOP) Edges Lower as Support Levels Are Tested - Chaikin Flow", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNcE9ScFlFNWQ2VEpoQjNCS3doY29VWEFmREE5cHdnOUxLdkdXSXE0MVFad1lHYll6emVFV2FTakRxcmhaRVVzaEcya0x1Yk00WU9aRUZUSWIyXzBkdHd0SnNXcDM5Um1sTGtpM0dzQTRpYkhpcnNMem5EbjQ4M1U5cXlINEZvTXJpeEsxdFFWcHBQelZPTmRZR1dqOW01WjhIWnpHRkFQN1llOEJtME5CVERpaEM3ZnZiZGd5SzZmVQ?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-11T07:00:00+00:00", "published_display": "11 Jul 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Preferred Stock (FBIOP) Edges Lower as Support Levels Are Tested - NAAIM Leverage", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxNSXprejRVR1NzYnF2SmQ2OGp1SFloUG80OGIyYUpNalpOdVB4ZE5lTGNaSFRwWnMwVGxvRTgxV3FWQ1VfM2ZyVmpJNjhUcXpVMTRjdnJBVTlPZ21EakVTVHNwekVTQlpfclVKRTdVRlNXdzRzMHo2S1FpbmtORXNEY1hoQkFtYkV5cHlZdFFCSmJsQlppZmQxUjRlclZ6OENVT2pZN05adVdVaklsSHJiMGNlSFRBaUt0dVIxVkdHQzdDUQ?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-11T07:00:00+00:00", "published_display": "11 Jul 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Preferred (FBIOP) Q1 2026 Earnings: EPS Misses Estimates by over 400%, Stock Declines - Interim Report", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxOVFFBQjhfeDVqSHI2Y1gySWdMYkE5OTdGMU5Gajk1R0RYNzdaeks5dXFyUXA5dnRGU1NCQVlHSG52SHdmdTk5WlJuQ2JoVnJvdTdPMWtnTDVoNjV2ZXdYR3ZKM2czRVBlb3FhekxEemQwSEpMSndoMkFrcW9MMTJzTGdxUlVNeUpNV0JZbDRQanpqSDkwZ2g3SFoxalkzR2tiU2t6c3pubWpYZGx1Z1lfMlY5bUFjQzZobkdPQ29LVEh2QmhGUlp4RHpzLTAxdm5KSEJpYlBPQmw5dw?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-11T07:00:00+00:00", "published_display": "11 Jul 2026 07:00", "sentiment": "negative", "sentiment_pct": 5, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (FBIOP) Q1 2026 Earnings: EPS Misses Estimates Significantly, Stock Declines - Earnings Weakness Phase", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwJBVV95cUxQRW1XbUd2SzlvVVluOGJldW9ZazNXRUZQWVZRc3Q3cmgxYnZJOURCOHdjYWR2b2JkMENJUDVKZk1vU1UyS0hOd3E5cGpmNU4wM3lRdlYtRmt1VjhhOFpKQk93VTJQX0drYUlSc3g3RTJGb1hXakRsbFpqSFRvYm9TdmxEelJ6UElEN3hsTllsUHlUY2JyckY0X19WTWxaUzNibmZtalM1QkxoNUQ5WHVHZUx6RXRnTXVUTVU3QkQ4NDZtYkZZR3BnZDkxeXRzNjVNREJhNjhRLWZLUDJMQ0hXeTdEUU9RQkxKOTJZd25uRXIxYm9jcWp1bzYzU1pnaFdhT2Z5RXJ4UzJNSGJsU3dkdzRUUlk4NWxVUEZ5NVdhelhnYXlWNE9J?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-10T17:36:44+00:00", "published_display": "10 Jul 2026 17:36", "sentiment": "negative", "sentiment_pct": 5, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech highlights its biotech portfolio strategy as a Nasdaq-listed micro-cap", "summary": "Fortress Biotech, a Nasdaq-listed biopharmaceutical company, emphasizes its strategy of a diversified portfolio managed through subsidiary companies and partnerships. This approach focuses on licensing, clinical development, and eventual commercialization of novel therapeutics, p", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/fortress-biotech-highlights-its-biotech-portfolio-strategy-as-a/69725670", "source_name": "AD HOC NEWS", "published_at": "2026-07-08T19:27:00", "published_display": "08 Jul 2026 19:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mustang Bio (MBIO) Registration Filing Summary", "summary": "Mustang Bio (MBIO) is a clinical-stage biopharmaceutical company focused on CAR T therapies, operating as a majority-controlled subsidiary of Fortress Biotech. The company has an accumulated deficit of $395.8 million, no product sales to date, and faces significant doubt about it", "url": "https://quartr.com/events/mustang-bio-inc-mbio-registration-filing_FP0KdRuG", "source_name": "Quartr", "published_at": "2026-07-07T19:11:20", "published_display": "07 Jul 2026 19:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech focuses on specialty pharma growth and licensing model", "summary": "Fortress Biotech pursues a portfolio strategy in specialty pharmaceuticals, building and licensing therapies through its partner companies, and diversifying its pipeline to mitigate risk. The company focuses on specialty and rare disease markets, aiming for premium pricing and st", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/fortress-biotech-focuses-on-specialty-pharma-growth-and-licensing-model/69715488", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T15:30:00", "published_display": "07 Jul 2026 15:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Inc highlights its specialty pharma model as investors assess long-term prospects", "summary": "Fortress Biotech Inc operates a specialty pharmaceutical and biotech portfolio strategy, utilizing a holding-style structure with multiple subsidiaries to develop product candidates across various disease areas like oncology and rare diseases. This approach aims to diversify risk", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/fortress-biotech-inc-highlights-its-specialty-pharma-model-as-investors/69680167", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-03T15:41:31", "published_display": "03 Jul 2026 15:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trading the Move, Not the Narrative: (FBIOP) Edition", "summary": "This article provides an AI-driven analysis for Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (NASDAQ: FBIOP), highlighting weak near-term sentiment but strong long-term potential. It offers three distinct institutional trading strategies\u2014P", "url": "https://news.stocktradersdaily.com/news_release/98/Trading_the_Move,_Not_the_Narrative:_FBIOP_Edition_062626055202_1782467522.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-26T05:52:00", "published_display": "26 Jun 2026 05:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Fortress Biotech Inc For: 24 June By Investing.com", "summary": "This article announces the filing of Form 4 for Fortress Biotech Inc. on June 24. It is a brief report from Investing.com, providing basic information about the regulatory filing. The content focuses on the public disclosure of insider transactions for the company.", "url": "https://za.investing.com/news/stock-market-news/form-4-fortress-biotech-inc-for-24-june-93CH-4343110", "source_name": "Investing.com South Africa", "published_at": "2026-06-25T22:11:08", "published_display": "25 Jun 2026 22:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Fortress Biotech, Inc. \u2013 NASDAQ:FBIO", "summary": "This article displays the \"Price to sales forward\" financial metric for Fortress Biotech, Inc. (NASDAQ: FBIO). The content is primarily a data presentation, indicating the company's financial overview on the TradingView platform.", "url": "https://www.tradingview.com/symbols/NASDAQ-FBIO/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T12:10:10", "published_display": "25 Jun 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Journey Medical (DERM) Stock Draws Fresh Price Target Split After Fortress Valuation Changes", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/journey-medical-derm-stock-draws-042922197.html", "source_name": "Simply Wall St.", "published_at": "2026-06-25T04:29:22+00:00", "published_display": "25 Jun 2026 04:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech (NASDAQ: FBIO) CFO receives 400,000 RSU award", "summary": "Fortress Biotech's CFO, Jin David, was granted 400,000 restricted stock units (RSUs) as equity compensation, increasing his total holdings to 1,651,571 shares. These RSUs will vest in four equal annual installments, with the first vesting on January 5, 2027, contingent on his con", "url": "https://www.stocktitan.net/sec-filings/FBIO/form-4-fortress-biotech-inc-insider-trading-activity-bf9173876cd9.html", "source_name": "Stock Titan", "published_at": "2026-06-25T02:42:14", "published_display": "25 Jun 2026 02:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Fortress Biotech, Inc. \u2013 NASDAQ:FBIO", "summary": "The article provides a financial snippet for Fortress Biotech, Inc. (NASDAQ: FBIO), focusing on its enterprise value to revenue forward metric. It displays the current value, change, and percentage change for this financial indicator, noting that the market is closed without rece", "url": "https://www.tradingview.com/symbols/NASDAQ-FBIO/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T00:42:14", "published_display": "25 Jun 2026 00:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Preferred Stock (FBIOP) Holds Steady Near Midpoint of Recent Range - PCR Moving Average", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOT2g0Z0JENXVoU1g3VFIxZjFDaDlKVUdHRnMyTEl3RFAzaWNHazIwci1aSzRkUW9RRWlIX1lRV3c0aGgtemY1dWpxMGlIRzlmZGpaZzZObXROeVFRTzRHdVlWdjJmT3J5VS0yRWhEMnNWRmxmZ1J1bXNPVzNKTENsRF84OXIxSDZ2Wldzcl84d1VHR2hTamRkQWpNWmlEZWNDQUV3cUplbjBKLVQ4SFo5SzNEWTFIaFA3TENhNjdSdlBJZU0?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-23T18:44:07+00:00", "published_display": "23 Jun 2026 18:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Preferred Stock (FBIOP) Faces Resistance, Slides 2.3% in Quiet Session - Early Entry Signals", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxPQnJLQ21idVFyVlRTdkpFOXVfT0h1emJVMGFlOVZKZmt3c1ZGY3ZrWTY1RXNDSTFLd0c1VWliMnBsWkJYV1U3VGV5Y1RCQm5KWmtLYVhRVFVWeTlWekhaUGxOdDUtdlhPdFBkVWFIOGUycUUtNjh5bFV2VkNiLWlCY1YxdVY1dFVPWUFScWRHQTgwZlNJR0laQ3dsNFBfMmpCXzh6T0NFVFB2TktRZXB5ZlJ0VVRUU25CRFFsNlA4ZTJWZlE?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Preferred Stock (FBIOP) Faces Resistance, Slides 2.3% in Quiet Session - Quote Data", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxPbThJeVZQNXotS3RiQk1zSkFIc29PUVpmWjJFMWVxWUR6V0IyU3BaYlh2czBaekRnd3UyNlZrd2FpcEZwWVAzd1RlVVhzc25iWFY0UTUtNGRhQkRxdW50Q01oRFVWdjJncnpnLXVrSndCZHFGakdRcHBJTjZfZHAtYkpOZlUwOFlVY05qSUtGampHX0wzNlhDT1JENU5pcVFGdjRYc2d1Sks1elNmYTlUTm11MnVBU2JrWVBsMTdjeDd1MGhxWnc?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech: Is It Time To Pay The Deferred Preferred Stock Dividends? (FBIO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNelREUjIyQ2pLUExaUmZWMVVTNXliRzBxbHpBODdfZWFsbm9USF9FenlxMGpOazhkT094dTRMd1Z5NXZjejlKT0E5bklHQkhsWHNxTzY5bzVZSzN0Mk5uY0Y4emJLajcwY1RyY3phdmhxVFhxVXdOdDFfSFpZWmVTd3lwdnV3c1B3eVlETVNkakJCNEhiVlV5M3c2MGJiOWNzVzdEN1NMcTV0a24wVl80?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Preferred (FBIOP) Gains 1.21% as Income Seekers Eye 9.375% Yield - Cumulative Volume", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPT0Q1UzZDQ1pDVzVVRWx4VWdsc3hwMmpSVWJ0c2JJclB5NTdyLVpVOGYyLTE5b2twZV9scXd4SjVjVkMzdWluVW5NdzNuRlduaHZwWlVwc1liZm9taHAxQklSOWRsa003X1BOMjhIUThKalJfU3RFM2tSbjdCb3JaQjFjV3pJYWVlbnhfekJsanVtekpLa3MyYTEwcndQODBDQ3hjNlB4YlZ6RzdzV196VXlDV0NpY0pq?oc=5", "source_name": "po-news-eg.net", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Preferred (FBIOP) Gains 1.21% as Income Seekers Eye 9.375% Yield - Standard Deviation", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOSTZ5WHVWdVl5Mkd2eFJGWXY0MWlpX0ZjZU9OVXpEVlp1MkJQcmN4MmRRNXBjZkYwcndxbzFXZ2dVWHRRTW9WdGhtbmFMR0FvZHpWb1lMb2RnSUpiS1ZFRUc3Ql9Pbk0zaWZuNmxWaU84ZkZMZnFSTXhLTFVSVU52SnQta0ZxVzRycmZxMGxxVklHZTJocFp5MzhWa042RTZ4RjllclV1Q1FiNzBRZEZocUM0YjNGUHpDMGN3Zw?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech to Participate in A.G.P.\u2019s Annual Virtual Healthcare Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/fortress-biotech-participate-g-p-123000153.html", "source_name": "GlobeNewswire", "published_at": "2026-05-18T12:30:00+00:00", "published_display": "18 May 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/fortress-biotech-q1-earnings-snapshot-205038341.html", "source_name": "Associated Press", "published_at": "2026-05-14T20:50:38+00:00", "published_display": "14 May 2026 20:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/fortress-biotech-reports-first-quarter-201000966.html", "source_name": "GlobeNewswire", "published_at": "2026-05-14T20:10:00+00:00", "published_display": "14 May 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSG1pQzVIRmhqTkhiWXozT29mTWM0UERfakxmOTZzdm5TZ24wZTVqLUpSWlFyWGVmYnlicGE3ZVYxOVotWU5naGM5aUZVakItUGJLTk1ZVE1mclRHd1N3N0FIWkV2TzFrT2lMNFRjcHhnVVBzTk5vNUFkLTgwNExtRWJYN1hVZzRkVjRlTktkNk1jcnpfQklCamN3NA?oc=5", "source_name": "Barron's", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech: The PRV Catalyst That Could Reprice This Microcap", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPQi14VVlUSUNmM1JubXFxZ19jVkNBOWpkU01zWEt6Mm4zTnZwSXRhZ3pMVFhFSmhCQUp4ZHZxUjNsUnZ0cUR4UEhRZkI3aERudlFhdTZFcUFxOVJGb044bElybWk1a2VPbnpqRFdGSzBRRHphdlVQYjVmZVNKd2tERUxFcENqZ252YWYtSnhHRXFwcGxkYnVGekZJdW91QUMwUDVQcEVqd2JRNm8?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-02-19T08:00:00+00:00", "published_display": "19 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T07:00:00+00:00", "published_display": "16 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_gFBVV95cUxPTFlzc3AzYmlzdG0zQXQ4eEd2TDJlT0h5bGlMVUdRd0JjLWd2Qm5kVU5oR3VWX19BVENjbXlqcVM3NFMwT0FDTHQwY05WNk96aGhpM3pQMWZWcExyeGVZaXFkeDVtMTlwVnM5RlNaTTNHYVhVYkFDQ3kwczlFeTlUN1huR1FJbHdBT2ZTajJ6VEFPVFI0MkZoMzRIMjc2Y182WEJpREFjZno4VzRDZF85R1lrdjNhVi1pYm01RHJDRTJmWHF0OHpMOXFyLTJuLWgydEFBX3JGTGtBSzlVSmdER2NnVUdJbERJVkRxOGo1MFlHMHZXMUxZU0hFOWxIdw?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-12T07:00:00+00:00", "published_display": "12 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 89, "total_relevant": 52, "sentiment_summary": {"positive": 4, "negative": 5, "neutral": 43, "score": 49, "total": 52, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 78, "events": [{"event": "general", "label": "Market update", "weight": 15.35, "count": 26}, {"event": "earnings", "label": "Earnings", "weight": 10.46, "count": 20}, {"event": "analyst", "label": "Analyst action", "weight": 1.65, "count": 3}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}], "positive_events": 4, "negative_events": 5}, "market_context": {"has_market_context": true, "latest_close": 18.88, "latest_week": "2026-07-31", "one_week_move": -0.1, "four_week_move": -7.5, "twelve_week_move": 39.8, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.164747, "market_dynamics_buy_signal": false, "relative_strength": 44.62256, "fair_value_gap": 80.6, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "positive", "expectation_probability": 55.3302, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-0.1% over one week, -7.5% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 48, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "dars.gov.et", "count": 10}, {"label": "TradingKey", "count": 7}, {"label": "TradingView", "count": 6}, {"label": "Market source", "count": 5}, {"label": "Stock Traders Daily", "count": 3}, {"label": "Seeking Alpha", "count": 3}, {"label": "AD HOC NEWS", "count": 2}, {"label": "GlobeNewswire", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 43}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 26}, {"label": "Earnings", "count": 20}, {"label": "Analyst action", "count": 3}, {"label": "Deals and strategy", "count": 1}, {"label": "Balance sheet", "count": 1}, {"label": "Regulatory and legal", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "49/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "78/100 classification confidence."}, {"label": "Company focus", "value": "43", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "5", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-0.1% over one week, -7.5% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Precision Trading with Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (FBIOP) Risk Zones"}], "updated_at": "2026-08-07T06:01:35.372938+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}